Business Context and Reporting Period
This Form 8-K Current Report from Alnylam Pharmaceuticals, Inc. covers events occurring on June 9, 2011, with the report filed on June 10, 2011. The filing details the results of the Company's 2011 Annual Meeting of Stockholders and a specific executive compensation adjustment approved by the Compensation Committee.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. This report focuses exclusively on corporate governance and executive compensation matters.
Material Changes and Events
Executive Compensation Adjustment
On June 9, 2011, the Compensation Committee approved an immediate increase in the annual base salary for John M. Maraganore, Ph.D., Chief Executive Officer. His salary was raised from $525,000 to $650,000. This adjustment was made to align his compensation with the 50th to 60th percentiles of the industry peer group, as his salary had remained unchanged since January 2008.
Annual Meeting Results
The 2011 Annual Meeting was held on June 9, 2011, with 42,359,262 shares issued and outstanding as of the April 29, 2011 record date. Key voting outcomes included:
- Director Elections: Stockholders re-elected Class I directors John M. Maraganore, Paul R. Schimmel, and Phillip A. Sharp. Terms for other directors (John K. Clarke, Victor J. Dzau, Marsha H. Fanucci, Steven M. Paul, and Kevin P. Starr) continued.
- Executive Compensation (Say-on-Pay): Stockholders approved the compensation of named executive officers in a non-binding advisory vote.
- Vote Frequency: Stockholders recommended an annual (One Year) frequency for future advisory votes on executive compensation.
- Auditor Ratification: Stockholders ratified the appointment of PricewaterhouseCoopers LLP as the independent auditor for the fiscal year ending December 31, 2011.
Guidance, Outlook, and Risks
The filing text does not provide financial guidance, future outlook, management commentary on business strategy, or specific risk factors. The document is limited to reporting the outcomes of the shareholder vote and the CEO salary adjustment.
Investor Verification Checklist
- Verify the impact of the CEO salary increase on the company's total executive compensation expense for the remainder of 2011.
- Review the full proxy statement for detailed breakdowns of the "Votes Withheld" and "Broker Non-Votes" to assess shareholder sentiment regarding the board and management.
- Confirm the specific terms of the re-elected directors' tenure and any potential changes to board composition in future years.
- Check subsequent filings for the company's financial performance, as this 8-K contains no operational or financial data.